Masafumi Toyoshima, MD, PhDFred Hutchinson Cancer Research Center Identification of Targeted Therapies for MYC-Amplified Ovarian Cancer By Functional Genomics The main goal of Dr. Toyoshima’s research is to investigate whether MYC synthetic lethal genes can be therapeutic targets for ovarian cancer in women whose MYC gene is amplified. Using a siRNA screening strategy this study […]
Read More
Jessica Bertout, PhD, VMDFred Hutchinson Cancer Research Center2013 Gilman Family Scholar High-Resolution Detection of Somatic Ovarian Cancer Mutations in Bodily Fluids Owing to a lack of effective screening tests, 80% of ovarian cancer patients are diagnosed in late stages of the disease at which point there are low survival rates. Methods that enumerate tumor cells […]
Read More
Toshi Taniguchi, MD, PhDFred Hutchinson Cancer Research Center Secondary Mutations of BRCA1/2 in BRCA 1/2 Mutated Ovarian Cancer with Primary Platinum Resistance Platinum compounds are key drugs for the treatment of ovarian cancer and often help patients gain initial remission. However, some patients do not respond, called “primary platinum resistance.” To understand why this happens, […]
Read More
Thomas Spies, PhDFred Hutchinson Cancer Research Center Survival Signaling by the NKG2D Immunoreceptor in Ovarian Cancer Cancers adopt diverse strategies for immune evasion to safeguard their survival. The activating immunoreceptor NKG2D and its tumor-associated ligand MICA are key components in the human lymphocyte defense against cancer. Dr. Spies has discovered that solid tumors including ovarian […]
Read More
Andre Lieber, MD, PhDFred Hutchinson Cancer Research Center Clonality Analysis in Ovarian Cancer In preliminary studies, Dr. Lieber’s laboratory has identified new markers for ovarian cancer ovca stem cells. In this new study, his team will continue to address the concept of ovarian cancer stem cells and the phenotypic plasticity of ovarian cancer cells. Dr. […]
Read More
M. Robyn Andersen, MPH, PhDFred Hutchinson Cancer Research Center 2017 James A. Harting Pilot Study Award RESTART: Learning to reduce stress and anxiety after treatment Many ovarian cancer patients experience distress for years after their diagnosis, even during periods of remission and stable disease. Studies have shown that changes in the nervous system and inflammatory […]
Read More
Christopher J. Kemp, PhDFred Hutchinson Cancer Research Center 2019 Sequoyah Electric Pilot Study Award Preclinical advancement of combination therapy targeting BAZ2A and EZH2 in ovarian clear cell carcinoma Ovarian cancer accounts for over 14,000 deaths in the United States every year. Although ovarian cancer has several subtypes, patients have been treated almost in the same […]
Read More